



# **Phoenix NP Announces Availability of FDA-Approved Zepbound (tirzepatide) Through Its Telehealth Weight Management Program Across Arizona**

*February 02, 2026*

PHOENIX, AZ - February 02, 2026 - PRESSADVANTAGE -

Phoenix NP, a women-focused telehealth medical practice based in Phoenix, Arizona, has announced the availability of FDA-approved Zepbound (tirzepatide) as part of its medical weight management services. The medication is now accessible to eligible patients across all Arizona service areas, including Phoenix, Scottsdale, Tempe, Chandler, Gilbert, Mesa, Tucson, Goodyear, Buckeye, Sedona, and surrounding communities. This development reflects Phoenix NP's continued expansion of evidence-based treatment options for women seeking medically supervised weight management without reliance on insurance coverage.

Zepbound, which contains the active ingredient tirzepatide, received FDA approval for chronic weight management in adults with obesity or overweight who have at least one weight-related medical condition. The medication belongs to a newer class of injectable therapies that act on both the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. By targeting these two metabolic pathways, tirzepatide supports appetite regulation, blood sugar control, and metabolic efficiency when used alongside nutrition and lifestyle guidance.

Phoenix NP operates entirely as a telehealth clinic, allowing patients throughout Arizona to access care remotely through scheduled video or phone consultations. All evaluations, follow-up visits, and ongoing support are provided by a licensed Women's Health Nurse Practitioner, with care delivery structured to accommodate evening and weekend availability. According to the clinic, the addition of FDA-approved Zepbound aligns with its clinical model of offering regulated, manufacturer-supplied medications rather than compounded alternatives.

The introduction of Zepbound comes at a time when access to prescription weight management therapies has shifted due to regulatory scrutiny of compounded medications and changing insurance coverage standards. Phoenix NP has positioned its services to address these changes by offering a direct-pay model that separates provider care from medication costs, with prescriptions sent to authorized partner pharmacies that dispense FDA-approved products.

?Tirzepatide represents an important advancement in how clinicians can address weight-related health concerns using regulated, well-studied therapies.? Founder and provider Jenny Vu said. ?Making FDA-Approved Zepbound available through a telehealth setting allows women across Arizona to receive consistent medical oversight, education, and follow-up without the delays that often accompany traditional care pathways.?

Zepbound is administered as a once-weekly injection and is typically initiated at a low dose, which may be adjusted over time based on clinical response and tolerability. As with other GLP-1 receptor agonist-based therapies, treatment is intended to complement broader lifestyle strategies rather than replace them. Phoenix NP provides individualized guidance on nutrition, daily habits, and realistic behavior changes, with the goal of supporting steady, medically appropriate outcomes.

Eligibility for Zepbound is determined through a comprehensive medical intake process that reviews health history, current conditions, and body mass index (BMI). Under FDA guidelines, the medication is indicated for adults with a BMI of 30 or higher, or 27 or higher in the presence of certain weight-related conditions. Final prescribing decisions are made by the licensed provider following this assessment, and ongoing monitoring is maintained throughout treatment.

Phoenix NP's telehealth platform includes access to an online patient portal that supports appointment scheduling, secure messaging, and follow-up coordination. Patients enrolled in the program receive continuity of care from the same provider, a feature the practice emphasizes as part of its clinical approach. The clinic also notes that its services are designed specifically for women, with consideration given to hormonal

changes, metabolic patterns, and life-stage factors that may influence weight management.

In addition to Phoenix and its metropolitan areas, FDA-approved Zepbound is available to patients in regional and outlying Arizona communities, including Tucson and Northern Arizona. Because care is delivered remotely, geographic proximity to a physical office is not required, provided patients reside within the state and meet clinical criteria.

The expansion of Zepbound access through Phoenix NP reflects broader trends in telehealth adoption and the integration of prescription therapies into virtual care models. By combining regulated medications with structured medical oversight, Phoenix NP aims to offer an alternative to insurance-dependent or in-person clinic-based services for patients.

Phoenix NP was established to address gaps in access to women-centered medical weight management, particularly for individuals who face scheduling constraints or limited local availability of specialized care. The clinic's services are delivered on a subscription basis for provider care, while medication costs are paid directly to dispensing pharmacies at set manufacturer pricing.

Further information about FDA-Approved Zepbound (tirzepatide), eligibility requirements, and Phoenix NP's telehealth services is available through the clinic's official website.

###

For more information about Phoenix NP, contact the company here: Phoenix NPMichael Lim(480) 382-0176info@phoenixnptealth.com1801 E Camelback Rd 102 1278, Phoenix, AZ 85016

## **Phoenix NP**

*Phoenix NP offers telehealth support for women using FDA-approved Wegovy and Zepbound. Patients receive clear guidance, steady follow up, and access to one provider through flexible online visits. Book a complimentary call to start your care.*

Website: <https://www.phoenixnp.com/>

Email: [info@phoenixnptealth.com](mailto:info@phoenixnptealth.com)

Phone: (480) 382-0176



